Latest Breaking News On - Cardiovascular outcomes - Page 1 : vimarsana.com

PACMAN-AMI: Addition of Alirocumab Lacks Benefit for Endothelial Function

Alirocumab added to high-intensity statin therapy did not further improve endothelial function in patients with acute myocardial infarction.

Daiichi Sankyo Europe GmbH: First-in-class cholesterol-lowering treatment NILEMDO? and its combination with ezetimibe, NUSTENDI?, approved in Europe to lower LDL cholesterol and reduce cardiovascular risk

NILEMDO? (bempedoic acid), a first-in-class, oral treatment and NUSTENDI? (bempedoic acid ezetimibe fixed-dose combination) receive label update approval from the European Commission as treatments

Ozempic Could Be Good For Your Heart Even If You Don't Lose Weight

The medicine behind Ozempic and Wegovy, called semaglutide, could have significant benefits for heart health, reducing the risk of stroke or cardiac arrest even in those who don't lose weight.

Ozempic: How semaglutide drugs can help with long-term weight loss

Researchers say GLP-1 weight loss medications such as Ozempic, Rybelsus, and Wegovy are effective for long-term weight loss as well as improving heart health

Obesity drug shows significant weight loss for at least four years, with fewer serious events, study finds